https://pittplusme.org/study/1495
A Study to Evaluate an Investigational Medication (BMS-986165) in Participants With Moderate to Severe Plaque Psoriasis
We're sorry. This study is closed and no longer recruiting participants.
STUDY BASICS
Have you been diagnosed with moderate-to-severe plaque psoriasis for at least 6 months? Are you a candidate for phototherapy or systemic therapy? If so, you may be eligible to participate in a study to measure how safe and effective an investigational study drug, BMS-986165, is in treating participants with psoriasis.
IRB: SSU00061184
- Bristol-Myers Squibb Company – IM011046, A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis (Pro00027919)
AGE:
18 and up
DURATION:
60 weeks
VISITS:
18 visits
LOCATION:
Falk Medical Building - Oakland
COMPENSATION:
$50 per visit
SHARE STUDY
MEET THE RESEARCHER
Laura Ferris
Laura Korb Ferris, MD, PhD, is Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.